Bristol-Myers Squibb has announced the 2015 recipients for three $300,000 research grants under its Partnering for Cure program, which this year, will go toward providing new insights on the immunopathology of HIV and the hepatitis B virus (HBV), according to a recent press release from the pharmaceutical company.

The funding program, originally founded by BMS in 2013, aims to transform clinical outcomes for patients with chronic viral diseases, namely HIV, hepatitis B and the hepatitis C virus (HCV) around the world. This year’s grants will focus on providing young researchers in Europe the opportunity to accelerate several promising initiatives that could help put an end to these viral epidemics.

The first project to receive funding, based in Spain, will look into better identifying HIV viral reservoirs. The second project, based in the Netherlands, will look into the role of B cells in chronic hepatitis B infections. The third research initiative, which is being conducted in Germany, will look into developing new pathways for long-term suppression of HIV.

Over the past two years, BMS’s Partnering for Cure program has provided $1.3 million in funding to new research initiatives in HIV, HBV and HCV.

For more information about the research program, click here.